Camptothecin
"Camptothecin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Descriptor ID |
D002166
|
MeSH Number(s) |
D03.132.151
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Camptothecin".
Below are MeSH descriptors whose meaning is more specific than "Camptothecin".
This graph shows the total number of publications written about "Camptothecin" by people in this website by year, and whether "Camptothecin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 | 1996 | 0 | 1 | 1 | 1998 | 0 | 1 | 1 | 2001 | 1 | 0 | 1 | 2002 | 0 | 1 | 1 | 2003 | 1 | 0 | 1 | 2004 | 3 | 0 | 3 | 2005 | 0 | 2 | 2 | 2006 | 1 | 2 | 3 | 2007 | 2 | 1 | 3 | 2009 | 2 | 1 | 3 | 2010 | 0 | 1 | 1 | 2011 | 0 | 3 | 3 | 2012 | 1 | 2 | 3 | 2013 | 1 | 2 | 3 | 2014 | 2 | 1 | 3 | 2016 | 4 | 2 | 6 | 2017 | 7 | 3 | 10 | 2019 | 2 | 0 | 2 | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Camptothecin" by people in Profiles.
-
Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020 12; 31(12):1709-1718.
-
Weiss J, Glode A, Messersmith WA, Diamond J. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther. 2019 08; 19(8):673-679.
-
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751.
-
Wainberg ZA, Alsina M, Soares HP, BraƱa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785.
-
Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs. 2017 11; 28(10):1086-1096.
-
Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Bioconjug Chem. 2017 11 15; 28(11):2747-2755.
-
Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, Pappo A, Dyer MA. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature. 2017 09 07; 549(7670):96-100.
-
Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10; 35(29):3338-3346.
-
Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 01; 23(19):5711-5719.
-
Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, Crane CH, O'Reilly EM, Lowery MA, Yu KH, Goodman KA, Wu AJ. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017 Dec; 56(12):1746-1753.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|